The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder

被引:3
|
作者
Rickels, Karl [1 ]
Gallop, Robert [2 ]
Cleary, Sean [3 ]
机构
[1] Univ Penn, Dept Psychiat, 3535 Market St,Suite 670, Philadelphia, PA 19146 USA
[2] West Chester Univ, Dept Math, Appl Stat Program, W Chester, PA USA
[3] Harcum Coll, Dept Gen Studies, Media, PA USA
关键词
adverse events; generalized anxiety disorder; attrition; TOLERABILITY;
D O I
10.1097/JCP.0000000000001027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose The time course of adverse events is an important factor for patient management. Clinicians are better able to prepare patients for specific adverse events, which leads to better treatment adherence. Methods Adverse events were followed longitudinally for 6 months during the open-label phase of a relapse prevention trial with 264 patients with generalized anxiety disorder. Adverse events were assessed at each treatment visit using a 21-item checklist. Logistic regression modeling, continuation ratio modeling, and hierarchical linear modeling were used to determine whether adverse events led to early attrition and whether adverse events decreased in enrolled patients over time. Findings Adverse events were found to have decreased highly significantly during treatment. A highly significant race effect was found in that whites had a significantly higher adverse event rate than did nonwhites. Early attrition rates were predicted by presence of nausea and fatigue, late attrition by dizziness, nervousness, and sexual dysfunction.
引用
下载
收藏
页码:258 / 260
页数:3
相关论文
共 50 条
  • [21] Venlafaxine (Velafax®) in the treatment of depressive disorder comorbid with generalized anxiety disorder
    Dzubur-Kutenovic, Alma
    Kucukalic, Abdulah
    Srkalovic, Azijada
    PSYCHIATRIA DANUBINA, 2007, 19 (04) : 389 - 389
  • [22] Potential for adverse events in patients with generalized anxiety disorder
    Frackiewicz-Koziol, EJ
    Sramek, JJ
    Cutler, NR
    ANNALS OF PHARMACOTHERAPY, 1998, 32 (01) : 132 - 134
  • [23] Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder
    Cooper, Alissa J.
    Narasimhan, Sneha
    Rickels, Karl
    Lohoff, Falk W.
    PSYCHIATRY RESEARCH, 2013, 210 (03) : 1299 - 1300
  • [24] Treatment of generalized anxiety disorder with venlafaxine: A series of 11 cases
    Johnson, MR
    Emmanuel, N
    Crawford, M
    Lydiard, RB
    Villareal, G
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (05) : 418 - 419
  • [25] FUNCTIONAL AND QUALITY OF LIFE IMPAIRMENT IN GENERALIZED ANXIETY DISORDER: EFFECT OF SHORT-TERM TREATMENT WITH PREGABALIN AND VENLAFAXINE-XR
    Mychaskiw, M. A.
    Alvir, J. M.
    Hoffman, D. L.
    Herman, B. K.
    Joshi, A.
    EUROPEAN PSYCHIATRY, 2009, 24
  • [26] Serotonin Transporter Gene Promoter Polymorphism Predicts Long-Term Treatment Response to Venlafaxine XR in Generalized Anxiety Disorder
    Lohoff, Falk W.
    BIOLOGICAL PSYCHIATRY, 2012, 71 (08) : 235S - 235S
  • [27] Functional and quality of life impairment in generalized anxiety disorder: Effect of short-term treatment with pregabalin and venlafaxine-XR
    Mychaskiw, M.
    Alvir, J.
    Herman, B. K.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 280 - 280
  • [28] Venlafaxine in depressive disorder comorbid with generalized anxiety disorder
    Kulenovic, A. Dzubur
    Kucukalic, A.
    Bravo-Mehmedbasic, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S466 - S467
  • [30] Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder
    F W Lohoff
    T D Aquino
    S Narasimhan
    P K Multani
    B Etemad
    K Rickels
    The Pharmacogenomics Journal, 2013, 13 : 21 - 26